- Home
- HWBK vs PBYI Comparison
HWBK vs PBYI Comparison
Compare HWBK & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HWBK | PBYI |
|---|---|---|
| Founded | 1865 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.4M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HWBK | PBYI |
|---|---|---|
| Price | $34.60 | $5.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 6.4K | ★ 644.4K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | ★ 259.86 | 59.87 |
| EPS | ★ 3.19 | 0.74 |
| Revenue | $77,904,000.00 | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.92 | ★ $7.05 |
| Revenue Growth | ★ 45.83 | N/A |
| 52 Week Low | $25.21 | $2.58 |
| 52 Week High | $35.95 | $6.12 |
Technical Indicators
Market Signals| Indicator | HWBK | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 75.39 | 54.71 |
| Support Level | $33.44 | $4.84 |
| Resistance Level | $34.20 | $5.11 |
| Average True Range (ATR) | 0.63 | 0.19 |
| MACD | 0.23 | 0.03 |
| Stochastic Oscillator | 95.35 | 83.18 |
Price Performance
Historical ComparisonAbout HWBK Hawthorn Bancshares Inc.
Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.